Urticaria| A Drug Pipeline Analysis Report 2018| Technavio

LONDON--(BUSINESS WIRE)--Jul 27, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat urticaria.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180727005539/en/

Technavio has published a new report on the drug development pipeline for urticaria, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only:

Urticaria: Market overview

Urticaria is a skin disorder, which is popularly termed as hives. It is a type of skin rash with red and itchy bumps. These rashes may cover an area of a few millimeters to several centimeters. They mostly last for a few days and do not leave any skin changes. The most common hives causing foods are nuts, chocolates, fish, tomatoes, eggs, fresh berries, and milk.

According to a senior market research analyst at Technavio, “Urticaria frequently occurs following an infection or an allergic reaction due to medication, insect bites, or food. It can also be triggered due to psychological stress, cold temperature, or vibration. It lasts for short duration and occurs equally in males and females; however, the long duration cases are common in females. Based on the duration and type, urticaria is subdivided into chronic urticaria, acute urticaria, chronic spontaneous urticaria, cold contact urticaria, chronic idiopathic urticaria, and chronic-antihistamine refractory urticaria.”

Urticaria: Segmentation analysis

This pipeline analysis report segments the urticaria market based on therapies employed (monotherapy), RoA (oral, subcutaneous, intravenous, and topical), therapeutic modality (monoclonal antibody, small molecule, and fusion protein), targets (IgE antibody, Bruton's tyrosine kinase (BTK), siglec-8 receptor, histamine, interleukin 1 (IL-1), humanized IL-5, spleen tyrosine kinase,histidine decarboxylase, and H1 receptor), MoA (anti-IgE antibody, BTK inhibitor, siglec-8 receptor antagonist, histamine H1 antagonist, humanized IL-5 antagonist, IL-1 inhibitor, spleen tyrosine kinase inhibitor, irreversible histidine decarboxylase inhibitor, and H1 receptor antagonist), geographical segmentation (Americas, EMEA, and APAC) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on RoA, more than 31% of the molecules that are being investigated for the treatment of urticaria are subcutaneous medication.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drugs under development Indications coverage

Drug Development Strategies

Therapies employed RoA Therapeutic modality Geographical coverage

Recruitment Strategies

Recruitment status Gender Age

Key Companies

Type of players Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180727005539/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 07/27/2018 03:05 PM/DISC: 07/27/2018 03:06 PM

http://www.businesswire.com/news/home/20180727005539/en